Cover Image
市場調查報告書

HIV-Integrase─ (EC 2.7.7.) :開發中產品分析

HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364867
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
HIV-Integrase─ (EC 2.7.7.) :開發中產品分析 HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 70 Pages
簡介

本報告提供以HIV-Integrase─ (EC 2.7.7.)為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

HIV-Integrase─ (EC 2.7.7.) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Critical Outcome Technologies Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • TGV-Laboratories
  • ViiV Healthcare Limited

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0170TDB

Summary

Global Markets Direct's, 'HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016', provides in depth analysis on HIV-1 Integrase (EC 2.7.7.) targeted pipeline therapeutics.

The report provides comprehensive information on the HIV-1 Integrase (EC 2.7.7.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for HIV-1 Integrase (EC 2.7.7.)
  • The report reviews HIV-1 Integrase (EC 2.7.7.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses HIV-1 Integrase (EC 2.7.7.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to HIV-1 Integrase (EC 2.7.7.) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for HIV-1 Integrase (EC 2.7.7.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding HIV-1 Integrase (EC 2.7.7.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • HIV-1 Integrase (EC 2.7.7.) Overview
  • Therapeutics Development
    • HIV-1 Integrase (EC 2.7.7.) - Products under Development by Stage of Development
    • HIV-1 Integrase (EC 2.7.7.) - Products under Development by Therapy Area
    • HIV-1 Integrase (EC 2.7.7.) - Products under Development by Indication
  • HIV-1 Integrase (EC 2.7.7.) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • HIV-1 Integrase (EC 2.7.7.) - Products under Development by Companies
  • HIV-1 Integrase (EC 2.7.7.) - Products under Development by Universities/Institutes
  • HIV-1 Integrase (EC 2.7.7.) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • HIV-1 Integrase (EC 2.7.7.) - Companies Involved in Therapeutics Development
    • Critical Outcome Technologies Inc.
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • TGV-Laboratories
    • ViiV Healthcare Limited
  • HIV-1 Integrase (EC 2.7.7.) - Drug Profiles
    • (cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (dolutegravir sodium + rilpivirine hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit HIV-I Integrase for HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabotegravir sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabotegravir sodium + rilpivirine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elvitegravir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-522 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-532 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-2048 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HIV-1 Integrase for HIV infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Integrase for HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T-169 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • HIV-1 Integrase (EC 2.7.7.) - Dormant Projects
  • HIV-1 Integrase (EC 2.7.7.) - Discontinued Products
  • HIV-1 Integrase (EC 2.7.7.) - Featured News & Press Releases
    • Feb 24, 2016: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir
    • Feb 23, 2016: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment
    • Jan 26, 2016: AHF Files Federal Lawsuit Against Gilead to Invalidate Patents on Key AIDS Drug
    • Dec 07, 2015: Health Canada Issues Notice of Compliance for Gilead's Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
    • Nov 23, 2015: European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
    • Nov 05, 2015: U.S. Food and Drug Administration Approves Gilead's Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
    • Nov 03, 2015: ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy
    • Oct 22, 2015: Gilead Announces Phase 3 Results for Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV
    • Sep 25, 2015: European CHMP Adopts Positive Opinion for Gilead's Single Tablet Regimen Genvoya for the Treatment of HIV
    • Jul 21, 2015: Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
    • May 06, 2015: ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy
    • Apr 15, 2015: Critical Outcome Technologies Receives First U.S. Patent For Next Generation HIV Treatment
    • Feb 26, 2015: Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide
    • Jan 15, 2015: Long-acting drug effectively prevents HIV-like infection in monkeys
    • Nov 06, 2014: Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Pipeline by Gilead Sciences, Inc., H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by TGV-Laboratories, H1 2016
  • Pipeline by ViiV Healthcare Limited, H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top